

ASX Release**Oventus signs further material agreements with two US sleep groups to deliver O2Vent® Sleep Treatment Platform to patients with sleep apnoea****Key points:**

- **Agreements signed with US sleep groups, Delaware Sleep Disorder Centres and Reliable Respiratory, to supply dental sleep medicine solutions across a total of 10 facilities**
- **Adds to news of first agreements signed in June and July with sleep groups in Canada and the US for the Oventus O2Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)**
- **Oventus expects to secure further agreements across its key target markets in the US, Canada and Australia over the next 12-24 months, with a view to significant scaling through to the end of CY2019 and CY2020; negotiations ongoing with multiple groups**
- **Oventus is strongly positioned to scale sales substantially following the announcement of a capital raise on 26 July: Placement of A\$7m and Entitlement Offer launched to raise A\$2.3m from existing shareholders**

Brisbane, Australia 15 August 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce it has signed further material agreements with US sleep medicine groups, Delaware Sleep Disorder Centres and Reliable Respiratory. The two companies will adopt the Company's O2Vent® Sleep Treatment Platform and 'lab in lab' business model for the treatment of obstructive sleep apnoea (OSA) across a total of 10 facilities divided between the two companies.

Delaware Sleep Disorder Centres is a leading sleep diagnosis and treatment group based in Newark, Delaware, in the US. Reliable Respiratory is a leading independently owned home respiratory and specialty medical equipment provider based in Massachusetts, in the US.

Under the agreements, Oventus is the exclusive supplier of dental sleep services for the treatment of OSA. The agreements initially cover 10 new sites: three sites in Delaware with Delaware Sleep Disorder Centres, and seven sites in New England. A minimum monthly quota of 20 O2Vent® devices will be delivered to patients per site.

The agreements will be officially launched as soon as the O2Vent® Optima oral device has received regulatory clearance from the US FDA (application pending approval) which Oventus expects to receive in 2H calendar 2019.

CEO of Oventus, Dr Chris Hart commented, "It is very encouraging to see strong continued interest from US sleep centres keen to deliver Oventus' highly efficacious sleep treatment platform to patients. Once we receive FDA clearance for our flagship device, the O2Vent® Optima, these agreements will operate under our 'lab in lab' business model. With the support of our recent capital raising, we are in a strong position to deliver on more agreements like these across our key markets of the US, Canada and Australia."

These US agreements follow announcements in June and July that Oventus had signed its first sleep medicine groups in Canada and the US under the same 'lab in lab' business model, where those groups also committed to selling minimum quantities of O2Vent® Optima devices. A number of additional contracts are being negotiated in Canada where both O2Vent® Optima and Oventus' unique complementary oral PEEP valve, ExVent™, which further increases efficacy, are both cleared for sale.

Early adoption is being driven by growing awareness from clinicians that the O2Vent® technology can deliver treatment outcomes comparable to the current standard of care – continuous positive airway pressure technology (CPAP) – for the majority of patients in a non-invasive manner. The 'lab in lab' model delivers fast outcomes for patients within a framework that is commercially attractive for sleep labs and dentists, a key driver of adoption.

Oventus is strongly positioned to significantly scale sales following its announcement of a capital raise on 26 July; raising A\$7 through a Placement and the launch of an Entitlement Offer to existing shareholders to raise up to a further A\$2.3 million. The Company expects to secure and announce further agreements across these key markets of Canada, the US and Australia over the next 12-24 months.

—ENDS—

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or investors@oventus.com.au
Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances or CPAP interfaces, Oventus O2Vent® devices manage the entire upper airway via a unique and patented built-in airway. O2Vent® devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent® devices are particularly designed for the many people that have nasal obstruction. They allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent® Optima device, to augment traditional oral appliance therapy by stabilising the airway. The ExVent™ valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment³. The O2Vent® Optima and ExVent™ provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

¹ Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

² Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

³ Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.